Specialized Cancer Center Support Grant

描述（由申请人提供）：加州大学圣地亚哥分校（UCSD）的摩尔癌症中心（MCC）是一个矩阵癌症中心，拥有来自18个大学系的225名成员。UCSD调查人员的同行评审资金为1.02亿美元（直接成本），其中3200万美元来自NCI。来自非同行审查来源的额外1 380万美元导致直接费用供资总额为1.158亿美元。一个新的27万平方英尺的多功能癌症中心大楼于2005年4月开放。它位于UCSD校园内，周围是其他几个主要的生命科学研究所和拉霍亚的470家生物技术公司，这里通常被称为生物技术的“金三角”。MCC是这个多产的癌症研究地区唯一的NCI指定的综合癌症中心。鉴于这一优势，摩尔癌症中心的长期愿景是成为南加州发现和测试预防、诊断和治疗癌症的新药物的主要中心。 新的MCC大楼是专门设计的：（1）促进医生和科学家之间的跨学科合作，在中心的癌症预防和控制，基础科学，临床和转化研究部门;（2）在一个公共和可访问的站点上汇集广泛的NCI支持的共享资源，以及（3）作为南加州公共和私营部门癌症转化研究人员的中心聚集地。自该大楼一年前开放以来，接受治疗性临床试验的患者人数增加了一倍多。本申请报告了11个共享资源和7个研究项目，反映了MCC的科学优势和目标。现有四个方案-癌症生物学、癌症遗传学、癌症预防和控制、癌症症状控制，三个是新的方案-血液系统恶性肿瘤、减少癌症差异和肿瘤生长、侵袭和转移。 本申请还总结了我们对MCC实验室和合作研究所研究的新疗法的部署计划。MCC的领导层在UCSD政府的支持下，将研究发现及其转化为有意义的进步以预防，改善和消除癌症负担作为最高优先事项。

DESCRIPTION (provided by applicant): The Moores Cancer Center (MCC) at the University of California, San Diego (UCSD) is a matrix cancer center with 225 members from 18 university departments. Peer-reviewed funding for UCSD investigators is $102 million (direct cost), of which $32 million originates from the NCI. An additional $13.8 million from non-peer reviewed sources results in total direct cost funding of $115.8 Million. A new 270,000 sq ft multipurpose Cancer Center building opened in April, 2005. It is located on the UCSD campus, surrounded by several other major life science research institutes and 470 biotechnology companies in La Jolla, which is commonly referred to as the "Golden Triangle" of biotechnology. The MCC is the only NCI designated comprehensive cancer center in this prolific cancer research region. Given this advantage, the long-term vision for the Moores Cancer Center is to become the major hub in Southern California for the discovery and testing of new agents for the prevention, diagnosis and treatment of cancer. The new MCC building was specifically designed to: (1) stimulate interdisciplinary collaboration between physicians and scientists in the Center's Divisions of Cancer Prevention and Control, Basic Science, and Clinical and Translational Research; (2) assemble in a common and accessible site the extensive NCI supported Shared Resources, and (3) act as a central gathering site for cancer translational researchers within the public and private sectors of Southern California. Since the building's opening only one year ago, patient accrual to therapeutic clinical trials has more than doubled. This application reports on 11 Shared Resources and seven Research Programs which reflect the scientific strengths and goals of the MCC. Four programs are existing - Cancer Biology, Cancer Genetics, Cancer Prevention and Control, Cancer Symptom Control, and three are new- Hematologic Malignancies, Reducing Cancer Disparities, and Tumor Growth, Invasion and Metastasis. This application also summarizes our plans for the deployment of new therapeutics originating from research occurring in MCC laboratories and collaborating institutes. The leadership of the MCC, supported by the UCSD administration, places the highest priority on research discovery and its translation into meaningful advances to prevent, ameliorate and eliminate the burden of cancer.